Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of June 2025, with the specific transaction date being June 5, 2025. The filing was submitted on June 6, 2025.
Key Financial Metrics
The filing details a share repurchase transaction executed through Merrill Lynch International. Key metrics for the transaction on June 5, 2025, include:
- Shares Purchased: 355,835 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,492.50p; highest price paid was 1,512.50p.
- Average Price: Volume-weighted average price paid was 1,503.99p.
- Treasury Holdings: Following this purchase, GSK holds 218,880,218 ordinary shares in treasury.
- Shares in Issue: 4,096,387,056 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.34% of total voting rights.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
This transaction is part of GSK's existing buyback programme. Since June 4, 2025, the company has purchased an aggregate of 745,835 ordinary shares. The purchase was effected pursuant to a non-discretionary agreement entered into with the broker on June 4, 2025. All shares purchased were executed on the London Stock Exchange (XLON); no purchases were made on CBOE Europe venues (CHIX or BATE) on this date.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results.
Investor Verification Checklist
- Verify the total number of treasury shares held (218,880,218) against the latest Form 20-F or quarterly reports.
- Confirm the remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Review the "Risk Factors" section of the 2024 Form 20-F referenced in the cautionary statement.
- Check the total voting rights denominator (4,096,387,056) for compliance with FCA Disclosure Guidance and Transparency Rules.